AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9288700 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensinogen
Number of subjects: 0
Study 9288700 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma renin activity and blood pressure
Number of subjects: 0
Study 8391792 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous enoxaparin, given twice daily
Number of subjects: 134
Study 8391792 — intervention group
Group type: COMPARATOR
Intervention: Continuous intravenous unfractionated heparin (UFH), adjusted-dose
Number of subjects: 134
Study 3521857 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone (7.5 mg)
Number of subjects: 91
Study 3521857 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 29363465 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA)
Number of subjects: 52
Study 29363465 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 52
Study 29363465 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 52
Study 29363465 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between BA and ACT
Number of subjects: 52
Study 27362245 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified Vero Cell Rabies Vaccine (PVRV), n = 702, 5-dose regimen
Number of subjects: 1449
Study 27362245 — intervention group
Group type: COMPARATOR
Intervention: Purified Chick Embryo Cell Vaccine (PCECV), n = 747, 5-dose regimen
Number of subjects: 1449
Study 27362245 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both vaccines
Number of subjects: 1449
Study 25224610 — intervention group
Group type: EXPERIMENTAL
Intervention: ARV-based prevention (tenofovir gel, oral tenofovir, oral Truvada)
Number of subjects: 164
Study 22926209 — intervention group
Group type: EXPERIMENTAL
Intervention: EV71 vaccine (160 U, 320 U, or 640 U antigen per dose)
Number of subjects: 360
Study 22926209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study 22926209 — intervention group
Group type: EXPERIMENTAL
Intervention: EV71 vaccine (2 doses)
Number of subjects: 360
Study 22926209 — intervention group
Group type: EXPERIMENTAL
Intervention: EV71 vaccine (1 dose)
Number of subjects: 360
Study 20729650 — intervention group
Group type: EXPERIMENTAL
Intervention: Stochastic resonance stimulation plus exercise (15 subjects)
Number of subjects: 30
Study 20729650 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation plus exercise (15 subjects)
Number of subjects: 30
Study 19151687 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional appliance
Number of subjects: 0
Study 19151687 — intervention group
Group type: EXPERIMENTAL
Intervention: Website support for data collection
Number of subjects: 0
Study 16000352 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (5 to 10 ppm)
Number of subjects: 420
Study 16000352 — intervention group
Group type: COMPARATOR
Intervention: Placebo (simulated flow)
Number of subjects: 420
Study 12520632 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolbutamide
Number of subjects: 16
Study 12520632 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Number of subjects: 16
Study 12520632 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 16
Study 11138572 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (5 mg)
Number of subjects: 9
Study 11138572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 8891887 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg aspirin once daily for 2 weeks
Number of subjects: 45
Study 8891887 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg ticlopidine twice daily for 2 weeks
Number of subjects: 45
Study 1671940 — intervention group
Group type: EXPERIMENTAL
Intervention: HIVAC‐1e vaccine
Number of subjects: 35
Study 1671940 — intervention group
Group type: COMPARATOR
Intervention: Standard NY strain vaccinia virus
Number of subjects: 35
Study 6147412 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromazepam 3 mg, three times daily
Number of subjects: 120
Study 6147412 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromazepam 6 mg, three times daily
Number of subjects: 120
Study 6147412 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 5 mg, three times daily
Number of subjects: 120
Study 30945797 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CsA) therapy
Number of subjects: 32
Study 30005825 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic steering intervention
Number of subjects: 100
Study 30005825 — intervention group
Group type: COMPARATOR
Intervention: Historic control (no magnetic assistance)
Number of subjects: 100
Study 27568646 — intervention group
Group type: EXPERIMENTAL
Intervention: DE+SM (8 group sessions)
Number of subjects: 107
Study 27568646 — intervention group
Group type: COMPARATOR
Intervention: DE (1 group session)
Number of subjects: 107
Study 22948377 — intervention group
Group type: EXPERIMENTAL
Intervention: Squat training with whole-body vibration (WBV; frequency = 35 to 40 Hz; amplitude = 4 mm) for 12 weeks, 3 times/week
Number of subjects: 26
Study 22948377 — intervention group
Group type: EXPERIMENTAL
Intervention: Squat training without WBV for 12 weeks, 3 times/week
Number of subjects: 26
Study 22948377 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 26
Study 21135365 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 162 mg plus clopidogrel 75 mg daily
Number of subjects: 113
Study 21135365 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 162 mg plus placebo daily
Number of subjects: 113
Study 17903081 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% lime juice
Number of subjects: 25
Study 17903081 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% lime juice
Number of subjects: 25
Study 17903081 — intervention group
Group type: COMPARATOR
Intervention: 0% (water-only)
Number of subjects: 25
Study 15771927 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen + Progestin (E+P) for 8 weeks
Number of subjects: 27
Study 15771927 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen (E) for 8 weeks
Number of subjects: 27
Study 15771927 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 27
Study 11989514 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection
Number of subjects: 23
Study 11989514 — intervention group
Group type: COMPARATOR
Intervention: Acemetacine and splinting
Number of subjects: 23
Study 9701721 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine users (n=15)
Number of subjects: 15
Study 9701721 — intervention group
Group type: COMPARATOR
Intervention: Nonusers (Control group, n=15)
Number of subjects: 15
Study 9081959 — intervention group
Group type: EXPERIMENTAL
Intervention: Pralidoxime (PAM) infusion, 1 gm 8 hourly for four days (total 12 gms)
Number of subjects: 72
Study 9081959 — intervention group
Group type: COMPARATOR
Intervention: Single bolus dose of Pralidoxime (PAM), 1 gm immediately after admission
Number of subjects: 72
Study 2528826 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection therapy with lidocaine
Number of subjects: 63
Study 2528826 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection therapy with lidocaine combined with a steroid
Number of subjects: 63
Study 2528826 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 63
Study 2528826 — intervention group
Group type: EXPERIMENTAL
Intervention: Vapocoolant spray with acupressure
Number of subjects: 63
Study 2528826 — intervention group
Group type: COMPARATOR
Intervention: Therapy without injected medication
Number of subjects: 63
Study 1067749 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc therapy (90 mg Zn2+ daily as zinc sulphate by mouth during the latter part of pregnancy)
Number of subjects: 20
Study 1067749 — intervention group
Group type: COMPARATOR
Intervention: Control group (no zinc therapy)
Number of subjects: 20
Study 31475941 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration exercise + squat training (WBV+ST)
Number of subjects: 41
Study 31475941 — intervention group
Group type: COMPARATOR
Intervention: Squat training (ST)
Number of subjects: 41
Study 28383410 — intervention group
Group type: EXPERIMENTAL
Intervention: Significant Histological Model (SHM) scoring system using serum AST, PLT, ALB, and HBV DNA (log10 IU/mL) levels
Number of subjects: 388
Study 25888270 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone plus prednisone
Number of subjects: 562
Study 25888270 — intervention group
Group type: COMPARATOR
Intervention: Prednisone alone
Number of subjects: 562
Study 23980351 — intervention group
Group type: EXPERIMENTAL
Intervention: Yiqi Huoxue Recipe (YHR) combined with Western drugs
Number of subjects: 61
Study 23980351 — intervention group
Group type: COMPARATOR
Intervention: Western medicine (control group)
Number of subjects: 61
Study 23980351 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 61
Study 21556957 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigator estimates of navigation intensity
Number of subjects: 139
Study 21556957 — intervention group
Group type: EXPERIMENTAL
Intervention: Total number of barriers to care
Number of subjects: 139
Study 18253162 — intervention group
Group type: EXPERIMENTAL
Intervention: BM/FMS group
Number of subjects: 311
Study 18253162 — intervention group
Group type: EXPERIMENTAL
Intervention: FMS group
Number of subjects: 311
Study 18253162 — intervention group
Group type: EXPERIMENTAL
Intervention: BM group
Number of subjects: 311
Study 18253162 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual curriculum)
Number of subjects: 311
Study 16701188 — intervention group
Group type: EXPERIMENTAL
Intervention: Preincisional (10 mL) and postoperative (10 mL) wound infiltration of 0.5% bupivacaine (group 1)
Number of subjects: 120
Study 16701188 — intervention group
Group type: EXPERIMENTAL
Intervention: Preincisional bupivacaine (10 mL) and postoperative infiltration of placebo (normal saline solution) (group 2)
Number of subjects: 120
Study 16701188 — intervention group
Group type: EXPERIMENTAL
Intervention: Preincisional placebo (10 mL) and postoperative bupivacaine (10 mL) (group 3)
Number of subjects: 120
Study 16701188 — intervention group
Group type: COMPARATOR
Intervention: Preincisional (10 mL) and postoperative infiltration of placebo (10 mL) (group 4)
Number of subjects: 120
Study 14715338 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 142
Study 14715338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study 11699175 — intervention group
Group type: EXPERIMENTAL
Intervention: Panavia 21 Opaque (PO)
Number of subjects: 64
Study 11699175 — intervention group
Group type: COMPARATOR
Intervention: Scotchbond Resin Cement (SRC)
Number of subjects: 64
Study 9377663 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin III (AT III) activity in the blood of patients with bladder carcinoma
Number of subjects: 0
Study 9377663 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 8163717 — intervention group
Group type: EXPERIMENTAL
Intervention: Moricizine (250 mg every 8 hours) for 14 days
Number of subjects: 12
Study 8163717 — intervention group
Group type: EXPERIMENTAL
Intervention: Moricizine (250 mg every 8 hours) for 7 days
Number of subjects: 12
Study 8163717 — intervention group
Group type: EXPERIMENTAL
Intervention: Moricizine (250 mg every 8 hours) for 6 days
Number of subjects: 12
Study 8163717 — intervention group
Group type: EXPERIMENTAL
Intervention: Moricizine (250 mg every 8 hours) for 13 days
Number of subjects: 12
Study 8163717 — intervention group
Group type: EXPERIMENTAL
Intervention: Moricizine (250 mg every 8 hours) for 7 days (discontinued)
Number of subjects: 12
Study 8163717 — intervention group
Group type: EXPERIMENTAL
Intervention: Moricizine (250 mg every 8 hours)
Number of subjects: 12
Study 2465517 — intervention group
Group type: EXPERIMENTAL
Intervention: Early vitrectomy
Number of subjects: 370
Study 2465517 — intervention group
Group type: COMPARATOR
Intervention: Conventional management
Number of subjects: 370
Study 29724590 — intervention group
Group type: EXPERIMENTAL
Intervention: PFNA Augmentation group
Number of subjects: 223
Study 29724590 — intervention group
Group type: COMPARATOR
Intervention: PFNA group
Number of subjects: 223
Study 28488687 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet intervention based on Nordic Nutrition Recommendations (NNR) 2004
Number of subjects: 61
Study 28488687 — intervention group
Group type: COMPARATOR
Intervention: Control group (ND-group)
Number of subjects: 61
Study 26271050 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose ciprofloxacin treatment for nalidixic acid-susceptible strains
Number of subjects: 161
Study 26271050 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose ciprofloxacin treatment for nalidixic acid-resistant strains
Number of subjects: 161
Study 26271050 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-dose ciprofloxacin treatment for nalidixic acid-susceptible strains
Number of subjects: 161
Study 26271050 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-dose ciprofloxacin treatment for nalidixic acid-resistant strains
Number of subjects: 161
Study 23975475 — intervention group
Group type: EXPERIMENTAL
Intervention: Affect management (AM) intervention
Number of subjects: 377
Study 23975475 — intervention group
Group type: COMPARATOR
Intervention: Standard skills-based HIV prevention intervention
Number of subjects: 377
Study 23975475 — intervention group
Group type: COMPARATOR
Intervention: General health promotion (HP) intervention
Number of subjects: 377
Study 21414384 — intervention group
Group type: EXPERIMENTAL
Intervention: Sectional matrix system combined with a separation ring (Palodent)
Number of subjects: 85
Study 21414384 — intervention group
Group type: COMPARATOR
Intervention: Circumferential matrix system in combination with a retainer (Tofflemire)
Number of subjects: 85
Study 18495377 — intervention group
Group type: EXPERIMENTAL
Intervention: 78 Gy
Number of subjects: 669
Study 18495377 — intervention group
Group type: COMPARATOR
Intervention: 68 Gy
Number of subjects: 669
Study 17144123 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin in usual doses (administered in addition to standard therapy)
Number of subjects: 126
Study 17144123 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (without indomethacin)
Number of subjects: 126
Study 14512803 — intervention group
Group type: EXPERIMENTAL
Intervention: Poly E ointment applied locally to 27 patients twice a week
Number of subjects: 51
Study 14512803 — intervention group
Group type: EXPERIMENTAL
Intervention: Poly E ointment plus poly E capsule therapy
Number of subjects: 51
Study 14512803 — intervention group
Group type: EXPERIMENTAL
Intervention: Poly E capsule therapy
Number of subjects: 51
Study 14512803 — intervention group
Group type: EXPERIMENTAL
Intervention: EGCG capsule therapy
Number of subjects: 51
Study 14512803 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment with green tea extracts
Number of subjects: 51
Study 14512803 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 51
Study 11119735 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG (500 mg/kg)
Number of subjects: 51
Study 11119735 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 51
Study 9179429 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled magnesium sulphate (180 mg)
Number of subjects: 10
Study 9179429 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 10
Study 8473554 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental lipid emulsion formulation of danazol (fasted)
Number of subjects: 11
Study 8473554 — intervention group
Group type: COMPARATOR
Intervention: Commercial formulation (hard gelatin capsule) (fasted)
Number of subjects: 11
Study 8473554 — intervention group
Group type: COMPARATOR
Intervention: Commercial formulation (hard gelatin capsule) (fed)
Number of subjects: 11
Study 8473554 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental lipid emulsion formulation of danazol (with food)
Number of subjects: 11
Study 3082023 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoprecipitate of human plasma (fibronectin)
Number of subjects: 31
Study 3082023 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fibronectin)
Number of subjects: 31
Study 29602274 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized Normative Feedback (PNF) intervention
Number of subjects: 571
Study 29602274 — intervention group
Group type: COMPARATOR
Intervention: Video game attention control
Number of subjects: 571
Study 27091420 — intervention group
Group type: EXPERIMENTAL
Intervention: LA-EP2006
Number of subjects: 308
Study 27091420 — intervention group
Group type: COMPARATOR
Intervention: Reference pegfilgrastim
Number of subjects: 308
Study 24506258 — intervention group
Group type: EXPERIMENTAL
Intervention: X-ray imaging combined with skin stimulation potential-guided percutaneous radiofrequency thermocoagulation of the Gasserian ganglion
Number of subjects: 60
Study 24506258 — intervention group
Group type: COMPARATOR
Intervention: C-arm X-ray-guided puncture through the foramen ovale
Number of subjects: 60
Study 23839118 — intervention group
Group type: EXPERIMENTAL
Intervention: Local lidocaine injection
Number of subjects: 48
Study 23839118 — intervention group
Group type: COMPARATOR
Intervention: Local saline injection (control)
Number of subjects: 48
Study 20816593 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 1767
Study 18058090 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 13
Study 18058090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 16162696 — intervention group
Group type: COMPARATOR
Intervention: BUD200 (100 microg of budesonide bid plus placebo)
Number of subjects: 40
Study 16162696 — intervention group
Group type: EXPERIMENTAL
Intervention: BUD200 + F (100 microg of budesonide bid plus 12 microg of formoterol)
Number of subjects: 40
Study 16162696 — intervention group
Group type: EXPERIMENTAL
Intervention: BUD (increased to 800 microg bid)
Number of subjects: 40
Study 12492909 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiocyanate/carbamide peroxide toothpaste (RCP) containing 0.5% SCN-, 0.1% H2O2, and 1450 p.p.m. fluoride
Number of subjects: 140
Study 12492909 — intervention group
Group type: COMPARATOR
Intervention: Triclosan toothpaste (Colgate Total) containing 0.3% triclosan, 2.0% PVM/MA, and 1450 p.p.m. fluoride
Number of subjects: 140
Study 11221809 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (300 mg/day)
Number of subjects: 100
Study 11221809 — intervention group
Group type: COMPARATOR
Intervention: Bedtime NPH insulin
Number of subjects: 100
Study 7856527 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable background therapy
Number of subjects: 209
Study 2119888 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachial approach to cardiac catheterization
Number of subjects: 202
Study 2119888 — intervention group
Group type: COMPARATOR
Intervention: Femoral approach to cardiac catheterization
Number of subjects: 202
Study 2119888 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachial approach
Number of subjects: 202
Study 2119888 — intervention group
Group type: COMPARATOR
Intervention: Femoral approach
Number of subjects: 202
Study 6988279 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional low carbohydrate diet
Number of subjects: 0
Study 6988279 — intervention group
Group type: COMPARATOR
Intervention: Modified fat diet (high in carbohydrate, low in fat, polyunsaturated to saturated fatty acids ratio of 1.5:1)
Number of subjects: 0
Study 6988279 — intervention group
Group type: COMPARATOR
Intervention: High carbohydrate diet
Number of subjects: 0
Study 31648501 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib combined with standard first-line chemotherapy
Number of subjects: 62
Study 31648501 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 62
Study 27052929 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheelchair posture support device (WPSD)
Number of subjects: 16
Study 27052929 — intervention group
Group type: COMPARATOR
Intervention: Regular care practice
Number of subjects: 16
Study 26215950 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel alone (90 mg/m² per week for six cycles of 28 days each; arm A)
Number of subjects: 52
Study 26215950 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel combined with bevacizumab (10 mg/kg once every 2 weeks; arm B)
Number of subjects: 52
Study 24268858 — intervention group
Group type: EXPERIMENTAL
Intervention: Low‐fluence photodynamic therapy (PDT)
Number of subjects: 32
Study 24268858 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab
Number of subjects: 32
Study 22172912 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid gel (RadiaPlex)
Number of subjects: 74
Study 22172912 — intervention group
Group type: COMPARATOR
Intervention: Petrolatum gel (Aquaphor)
Number of subjects: 74
Study 19240602 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for unruptured MCA aneurysms
Number of subjects: 37
Study 19240602 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for ruptured MCA aneurysms
Number of subjects: 37
Study 19240602 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment for both unruptured and ruptured MCA aneurysms
Number of subjects: 37
Study 17919379 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleural drainage using central venous catheter (Group A)
Number of subjects: 46
Study 17919379 — intervention group
Group type: COMPARATOR
Intervention: Simple aspiration by thoracentesis (Group B)
Number of subjects: 46
Study 10972645 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix (ADM) allograft
Number of subjects: 12
Study 10972645 — intervention group
Group type: COMPARATOR
Intervention: Autogenous free gingival graft (FGG)
Number of subjects: 12
Study 8726155 — intervention group
Group type: EXPERIMENTAL
Intervention: Metered Dose Inhaler (MDI) - 2 puffs or 200 micrograms
Number of subjects: 23
Study 8726155 — intervention group
Group type: EXPERIMENTAL
Intervention: Jet Nebulizer - 5 minutes of nebulization with 100 micrograms/kg
Number of subjects: 23
Study 1559290 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily wear or extended wear schedule
Number of subjects: 30
Study 1559290 — intervention group
Group type: COMPARATOR
Intervention: Pre-lens wear
Number of subjects: 30
Study 1559290 — intervention group
Group type: COMPARATOR
Intervention: Different wear schedules and lens types
Number of subjects: 30